Liquid formulation of a novel non-fluorinated topical quinolone, T-3912, utilizing the synergic solubilizing effect of the combined use of magnesium ions and hydroxypropyl-β-cyclodextrin

Journal of Controlled Release

Volumn 86, Issue 1, 2003, Pages 101-113

  Yamakawa, Tetsumi ^a   Nishimura, Setsuko ^a  

^a TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

Cyclodextrins; Magnesium ion; Polyvinylpyrrolidone; Quinolone; Solubility; Stability

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTIINFECTIVE AGENT; EYE DROPS; MAGNESIUM ION; POVIDONE; QUINOLONE DERIVATIVE; T 3912; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; 4 QUINOLONE DERIVATIVE; BETA CYCLODEXTRIN DERIVATIVE; CYCLODEXTRIN; MAGNESIUM; QUINOLINE DERIVATIVE; T3912;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; LIGHT EXPOSURE; LIQUID; PH; PKA; PRIORITY JOURNAL; REFRIGERATOR; CHEMISTRY; DRUG POTENTIATION; SOLUBILITY; TOPICAL DRUG ADMINISTRATION;

4-QUINOLONES; ADMINISTRATION, TOPICAL; ANTI-INFECTIVE AGENTS; BETA-CYCLODEXTRINS; CHEMISTRY, PHARMACEUTICAL; CYCLODEXTRINS; DRUG SYNERGISM; MAGNESIUM; QUINOLINES; SOLUBILITY;

EID: 0037426683     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00367-X     Document Type: Article

References (38)

1. Yamakawa T., Mitsuyama J., Hayashi K. In-vitro and in-vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J. Anitimicorb. Chemother. 49:2002;455-465.
2. Sweetana S., Akers M.J. Solubility principles and practices for parenteral drug dosage form development. PDA J. Pharm. Sci. Technol. 50:1996;330-342.
3. Nema S., Washkuhn R.J., Brendel R.J. Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol. 51:1997;166-171.
4. Spurlock C.H. Increasing solubility of enoxacin and norfloxacin by means of salt formation. J. Parent. Sci. Technol. 40:1986;70-72.
5. Guyot M., Fawaz F., Bildet J., Bonini F., Lagueny A.-M. Physicochemical characterization and dissolution of norfloxacin/cyclodextrin inclusion compounds and PEG solid dispersions. Int. J. Pharm. 123:1995;53-63.
6. 3+. J. Therm. Anal. 51:1998;1009-1021.
7. Ross D.L., Riley C.M. Physicochemical properties of the fluoroquinolone antimicrobials: III. Complexation of lomefloxacin with various metal ions and the effect of metal ion complexation on aqueous solubility. Int. J. Pharm. 87:1992;203-213.
8. T. Shinmura, O. Ohashi, I. Takakura, Medicinal composition conatining pyridone carboxylic acid or its salt and stabilization of solution of pyridone carboxylic acid or its salt, Japanese Patent 05-058895, 1993.
9. Bailey A.J.G., Cole A., Goodfield J., May P.M., Dreyfuss M.E., Midgley J.M., Williams D.R. The complexation of transition series metal ions by nalidixic acid and related methoxyquinolones: its influence on partition coefficients with reference to antibacterial activity. Int. J. Pharm. 22:1984;283-290.
10. Fleming L.W., Moreland T.A., Stewart W.K., Scott A.C. Ciprofloxacin and antacids. Lancet. Aug 2; 2:1986;294.
11. Okhamafe A.U., Akerele J.O., Chukuka C.S. Pharmacokinetic interaction of norfloxacin with some metallic medicinal agents. Int. J. Pharm. 68:1991;11-18.
12. Shimada J., Shiba K., Oguma T., Miwa H., Yoshimura Y., Nishikawa T., Okabayashi Y., Kitagawa T., Yamamoto S. Effect of antacid on absorption of the quinolone lomefloxacin. Antimicrob. Agents Chemother. 36:1992;1219-1224.
13. Timmers K., Sternglanz R. Ionization and divalent cation dissociation constants of nalidixic and oxolinic acids. Bioinorg. Chem. 9:1978;145-155.
14. Kelly R., Schultz T. A comparison of the chelation potentials of ofloxacin, ciprofloxacin, norfloxacin and nalidixic acid. Pharm. Res. 6:1989;S139.
15. Okabayashi Y., Hayashi F., Terui Y., Kitagawa T. Studies on the interaction of pyridone carboxylic acids with metals. Chem. Pharm. Bull. 40:1992;692-696.
16. Ross D.L., Riley C.M. Physicochemical properties of the fluoroquinolone antimicrobials: V. Effect of fluoroquinolone structure and pH on the complexation of various fluoroquinolones with magnesium and calcium ions. Int. J. Pharm. 93:1993;121-129.
17. Turel I., Bukovec N., Farkas E. Complex formation between some metals and a quinolone family member (ciprofloxacin). Polyhedron. 15:1996;269-275.
18. Ma H.H.M., Chiu F.C.K., Li R.C. Mechanistic investigation of the reduction in antimicrobial activity of ciprofloxacin by metal cations. Pharm. Res. 14:1997;366-370.
19. Li R.C., Nix D.E., Schentag J.J. Interaction between ciprofloxacin and metal cations: its influence on physicochemical characteristics and antibacterial activity. Pharm. Res. 11:1994;917-920.
20. Cruz M.S.R., Alonso I.G., Sánchez-Navarro A., Marinero M.L.S. In vitro study on the interaction between quinolones and polyvalent cations. Pharm. Acta Helv. 73:1999;237-245.
21. Kibbe A.H. Handbook of Pharmaceutical Excipients. 3rd Edition: 2000;165-168 American Pharmaceutical Association, Washington, DC.
22. Loftsson T., Brewster M.E. Pharmaceutical application of cyclodextrins: 1. Drug solubilization and stabilization. J. Pharm. Sci. 85:1996;1017-1025.
23. Loftsson T., Másson M. Cyclodextrins in topical drug formulations: theory and practice. Int. J. Pharm. 225:2001;15-30.
24. Loftsson T., Friǒriksdóttir H., Thorisdóttir S., Stefánsson E. The effect of hydroxypropylmethylcellulose on the release of dexamethasone from aqueous 2-hydroxypropyl-β-cyclodextrin formulation. Int. J. Pharm. 104:1994;181-184.
25. Loftsson T., Guǒmundsdóttir T., Friǒriksdóttir H. The influence of water-soluble polymers and pH on hydroxypropyl-β-cyclodextrin of drugs. Drug Dev. Ind. Pharm. 22:1996;401-405.
26. Redenti E., Szente L., Szejtli J. Drug/cyclodextrin/hydroxy acid multicomponent systems: Properties and pharmaceutical applications. J. Pharm. Sci. 89:2000;1-8.
27. Albert A., Serjeant E.P. Determination of Ionization Constants: A Laboratory Manual. 3rd Edition: 1984;Chapman and Hall, London, New York.
28. López-Alemany A., Móntés-Micó R., Garcia-Valldecabres M. Ocular physiology and artificial tears. J. Am. Optom. Assoc. 70:1999;455-460.
29. Martin A., Bustamante P., Chun A.H.C. Physical Pharmacy. 4th Edition: 1993;257-260 Lea and Febiger, Philadelphia, PA.
30. Krishnamoorthy R., Mitra A.K. Complexation of weak acids and bases with cyclodextrins: Effects of substrate ionization on the estimation and interpretation of association constants. Int. J. Pharm. Advances. 1:1996;329-343.
31. Higuchi T., Connors K.A. Phase-solubility techniques. Adv. Anal. Chem. Instr. 4:1965;117-212.
32. Usui F., Maeda K., Kusai A., Nishimura K., Yamamoto K. Inhibitory effect of water soluble polymers on precipitation of RS-8359. Int. J. Pharm. 154:1997;59-66.
33. Thompson D.O. Cyclodextrins-enabling excipients: Their presence and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. 14:1997;1-104.
34. Chapter 11 Mesens J.L., Putterman P. Pharmaceutical applications of 2-hydroxypropyl β-cyclodextrin. Duchéne D. New Trends in Cyclodextrins and Derivatives. 1991;369-407 Editions de Sante, Paris.
35. Irie T., Uekama K. Pharmaceutical applications of cyclodextrins: III. Toxicological issues and safety evaluation. J. Pharm. Sci. 86:1997;147-162.
36. Loftsson T., Stefánsson E. Effect of cyclodextrins on topical drug delivery to the eyes. Drug Dev. Ind. Pharm. 23:1997;473-481.
37. Saarinen-Savolaine P., Järviner T., Araki-Sasaki K., Watanabe H., Urtti A. Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line. Pharm. Res. 15:1998;1275-1280.
38. Loftsson T. Increasing the cyclodextrin complexation of drugs and drug bioavailability through addition of water-soluble polymers. Pharmazie. 53:1998;733-740.